Cite
HARVARD Citation
Masuishi, T. et al. (2020). Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. Oncologist. pp. e1614-e1620. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Masuishi, T. et al. (2020). Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. Oncologist. pp. e1614-e1620. [Online].